- Home
- NUWE vs EOCN Comparison
NUWE vs EOCN Comparison
Compare NUWE & EOCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NUWE | EOCN |
|---|---|---|
| Founded | 1999 | N/A |
| Country | United States | Israel |
| Employees | N/A | 6 |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2M | 3.6M |
| IPO Year | 2012 | 2014 |
Fundamental Metrics
Financial Performance| Metric | NUWE | EOCN |
|---|---|---|
| Price | $0.88 | $3.50 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 3.0M | 2.2K |
| Earning Date | 05-05-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,270,000.00 | N/A |
| Revenue This Year | $11.14 | N/A |
| Revenue Next Year | $18.51 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.08 | $3.33 |
| 52 Week High | $6.40 | $3.66 |
Technical Indicators
Market Signals| Indicator | NUWE | EOCN |
|---|---|---|
| Relative Strength Index (RSI) | 43.23 | N/A |
| Support Level | $0.71 | N/A |
| Resistance Level | $1.20 | N/A |
| Average True Range (ATR) | 0.09 | 0.00 |
| MACD | 0.06 | 0.00 |
| Stochastic Oscillator | 18.82 | 0.00 |
Price Performance
Historical ComparisonAbout NUWE Nuwellis Inc.
Nuwellis Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Nuwellis has one reportable segment: fluid overload.
About EOCN Eocene Ltd. Ordinary Shares
Eocene Ltd is a GI-focused medtech and biopharmaceutical company focused on advancing solutions across gastrointestinal disease management, GI oncology and related therapeutic areas. Its wholly owned subsidiary develops medical devices for postoperative colorectal care, including CG-100, an intraluminal bypass device intended to protect colorectal anastomoses and reduce the need for diverting stomas. The company's therapeutic portfolio includes Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule being evaluated in liver disease and oncology indications, including gastrointestinal cancers.